ERRATUM

Erratum to: Prognostic factors for brain metastases from non-small cell lung cancer with *EGFR* mutation: influence of stable extracranial disease and erlotinib therapy

Akimasa Sekine¹ · Hiroaki Satoh² · Tae Iwasawa³ · Katsumi Tamura⁴ · Kenji Hayashihara⁵ · Takefumi Saito⁵ · Terufumi Kato¹ · Mito Arai⁶ · Koji Okudela⁷ · Kenichi Ohashi⁷ · Takashi Ogura¹

Published online: 23 April 2015
© Springer Science+Business Media New York 2015

Erratum to: Med Oncol (2014) 31:228
DOI 10.1007/s12032-014-0228-9

The original version of this article unfortunately contained a mistake. Table 3 was published with incorrect values. The corrected Table 3 is given below. The authors regret the inconvenience caused to the readers in this regard.

The online version of the original article can be found under doi:[10.1007/s12032-014-0228-9](https://doi.org/10.1007/s12032-014-0228-9).

✉ Akimasa Sekine
Akimasa.Sekine@gmail.com

- ¹ Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Tomioka-Higashi 6-16-1, Kanazawa-ku, Yokohama, Japan
- ² Department of Internal Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan
- ³ Department of Radiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
- ⁴ Department of Radiology, National Hospital Organization, Ibaraki-Higashi National Hospital, Ibaraki, Japan
- ⁵ Department of Respiratory Medicine, National Hospital Organization, Ibaraki-Higashi National Hospital, Ibaraki, Japan
- ⁶ Department of Radiology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
- ⁷ Department of Pathology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

Table 3 Treatment history after brain metastases diagnosis

Treatment	<i>EGFR</i> mutation status		<i>p</i> value
	<i>EGFR</i> mutant (89)	Wild-type (108)	
Brain metastasectomy			
Yes/no	5/84	5/103	0.76
Radiotherapy			
Yes/no	57/32	87/21	0.010*
WBRT	21	28	
Radiosurgery	28	43	
Both WBRT and radiosurgery	8	16	
EGFR-TKIs			
Yes/no	66/23	26/82	<0.0001*
Gefitinib	34	8	
Erlotinib	12	15	
Both gefitinib and erlotinib	20	3	

WBRT whole brain radiotherapy

* $p < 0.05$